AME and Lilly collaborate on therapeutic candidates
Applied Molecular Evolution has agreed to optimize two protein therapeutic candidates for Eli Lilly and Company.
Applied Molecular Evolution has agreed to optimize two protein therapeutic candidates for Eli Lilly and Company.
The goal of the collaboration is to apply AME's proprietary AMEsystem directed molecular evolution technology to create optimised versions of both a growth factor and an antibody candidate for clinical development. Under the terms of the agreement, AME will receive an upfront fee and has the potential to receive milestone payments and royalties on any products resulting from the collaboration.
'Our third agreement with Lilly is a testament to AME's track record of delivering successfully optimized protein therapeutic candidates as well as the power of the AMEsystem to potentially improve the function of both growth factor and antibody therapeutic candidates', commented Dr William D Huse, president, ceo and chairman of AME. 'The continued adoption of AME's technology by Lilly and other world-leaders in protein therapeutic development emphasises the importance for biotherapeutic candidates to undergo optimisation prior to clinical evaluation and provides continued support for the collaborative component of AME's business model.'